Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Acquired | Acquired

Total Raised




About Peninsula Pharmaceuticals

Peninsula Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing antibiotics to treat life-threatening infections. The lead antibiotic candidate, Doripenem for injection, is currently in Phase III clinical trials for the treatment of serious bacterial infections in hospitalized patients. Peninsula's other product candidate, PPI-0903, is an intravenous broad-spectrum antibiotic for the treatment of severe and difficult to treat infections. Peninsula completed dosing in a Phase I trial for PPI-0903 in healthy volunteers in the United Kingdom in September 2004.

Peninsula Pharmaceuticals Headquarter Location

1751 Harbor Bay Parkway

Alameda, California, 94502,

United States


Latest Peninsula Pharmaceuticals News

CymaBay Announces the Appointment of Paul F. Truex and Robert J. Weiland to its Board of Directors

Mar 28, 2016

03/28/2016 | 04:02pm US/Eastern (You can enter multiple email addresses separated by commas) Message : *Required fields NEWARK, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced the appointment of Paul F. Truex and Robert J. Weiland to the company’s Board of Directors, effective April 1, 2016. "I would like to welcome Paul Truex and Bob Weiland to our Board. Both have deep strategic and operational experience, having held senior leadership roles in both large-cap pharmaceutical and development stage biotechnology companies,” said Harold Van Wart, Ph.D., Chief Executive Officer of CymaBay. “Paul brings both business acumen and operational experience to the board. He has a track record of providing leadership at small cap biopharmaceutical companies. Bob has a wealth of experience in business and commercialization strategy, including an in-depth knowledge of the lipid lowering market from his previous work at Abbott Laboratories. As we continue to advance CymaBay through the next stage in its product development objectives, it is important we have highly qualified industry experts on our board who can provide guidance based on significant experience.” Paul Truex is currently President and CEO of Anthera Pharmaceuticals. He was responsible for negotiating Anthera’s product licenses for both blisibimod, the company’s anti-BAFF peptibody program from Amgen, and recently, Sollpura™, an enzyme replacement product from Eli Lilly & Company. During his career, Mr. Truex has been involved with over $500 million in financings and over $1 billion in strategic in-licensing, out-licensing, and merger and acquisition transactions. Prior to founding Anthera, he was a Founder, Director, President & CEO of Peninsula Pharmaceuticals. During that time, he negotiated both of Peninsula’s product agreements with Shionogi & Co., Ltd. (Doribax®, doripenem) and Takeda Chemical Industries (Teflaro®, ceftaroline). Peninsula was sold to Johnson & Johnson for $245 million and the remaining entity, Cerexa, was subsequently acquired for $480 million. Prior to Peninsula, Mr. Truex was VP of Commercial Development of Versicor Incorporated (acquired by Pfizer) where he directed early commercial efforts in infectious disease. Prior to joining Versicor, Mr. Truex worked at Eli Lilly and Company where he served in various marketing and sales roles during the launch of three different products for the primary care physician market. His business development experience includes the Lilly ICOS LLC joint venture for the development of Cialis® and two product divestitures (anidulafungin, Eraxis® and loracarbef, Lorabid®). Mr. Truex obtained a Master's of Business Administration in Marketing and Finance from Indiana University and a Bachelor of Arts degree in Economics from the University of Waterloo. Robert J. “Bob” Weiland is a seasoned commercial executive, having held senior leadership roles in both large-cap pharma and biotechnology companies. Most recently, Bob worked at Baxter International, where he served as Vice President, Strategy for Baxter International, and where he led the reconstruction of Baxter’s worldwide go-to-market strategy. Prior to that, he was Baxter International’s Vice President, Corporate Development where he was responsible for Baxter’s global business development organization and shared leadership responsibilities for Baxter’s $200 million Venture Fund. Bob initially joined Baxter as its Vice President, Strategy & Portfolio Planning for Baxter’s BioScience business. In this role he led strategy development, including specialty therapeutics business development, and strategic portfolio management for Baxter’s $5.6 billion Bioscience business, which has since been spun off as an independent biotechnology company, Baxalta. Prior to Baxter, Mr. Weiland was VP of Operations and Strategic Analytics for Takeda Pharmaceuticals North America. Before Takeda, he headed the clinical, commercial and operational activities for the Surgery business unit of The Medicines Company as its Vice President and General Manager. Prior to that, he served for more than 14 years in a variety of senior domestic and international Marketing, General Management and Business Development roles at Abbott Laboratories, including the in-licensing, launch and subsequent building of TriCor, the foundation of Abbott’s lipid-lowering franchise. Mr. Weiland earned a Bachelor of Science Degree from DeSales University, Center Valley, Pennsylvania and a Master's in Business Administration in Finance and Marketing from The Wharton School at the University of Pennsylvania. About CymaBay CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. CymaBay’s product candidate MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed a pilot Phase 2 study of MBX-8025 in patients with homozygous familial hypercholesterolemia and has an ongoing Phase 2 study in patients with primary biliary cholangitis. Arhalofenate, CymaBay’s other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. For additional information about CymaBay visit . Contacts:Sujal ShahCymaBay Therapeutics, Inc.(510) 293-8800sshah@cymabay.comorHans VitzthumLifeSci Advisors, © GlobeNewswire 2016 Latest news on CYMABAY THERAPEUTICS INC 04:02p

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Peninsula Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Peninsula Pharmaceuticals is included in 1 Expert Collection, including Pharma Startups.


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.